Grants and Contributions:

Back to search

Title:

Covid 19 Vaccine: Manufacturing Feasibility Study and Engineering Design

Agreement Number:

959304

Agreement Value:

$2,103,150.00

Agreement Date:

Nov 1, 2020 - Oct 31, 2021

Description:

The purpose of the funding will be to support a feasibility assessment and detailed engineering design for the expansion of Therapure’s current mammalian cell culture (MCC) capacity in support of VBI’s coronavirus vaccine as well as other MCC projects and coronavirus vaccines that require insect cell/baculovirus expression systems and potentially adeno viral vectors. The two areas at Therapure’s current biomanufacturing facility that will be assessed to support pandemic vaccine manufacturing: •Existing space within the facility •Extension of the existing space with access to some of the existing utilities and all other systems such as Quality, Project Management, Finance and IT

Organization:

National Research Council Canada

Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Location:

Mississauga, Ontario, CA L5N 8H9

Reference Number:

172-2020-2021-Q3-959304

Agreement Type:

Contribution

Report Type:

Grants and Contributions

Recipient Business Number:

720950070

Recipient Type:

For-profit organization

Additional Information:

This agreement has been amended 1 time(s). The end date of this agreements has been modified by 123 days.

Amendment Date

Jun 28, 2021

Recipient's Legal Name:

Resilience Biotechnologies Inc.

Federal Riding Name:

Mississauga--Streetsville

Federal Riding Number:

35063

Program:

Industrial Research Assistance Program – Contributions to Firms

Program Purpose:

Coverage:

IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.

NAICS Code:

325410

Amendments:

See Amendments